Tolebrutinib (SAR442168)

Tolebrutinib · Sanofi

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Tolebrutinib (SAR442168), covering 2025-06-18 to 2026-01-07. Get the full timeline:

Most recent: Clinical Trial Update: Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) [Phase 3]

See pricing